Literature DB >> 25862438

Prioritizing precision medicine for prostate cancer.

G Attard1, H Beltran2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25862438     DOI： 10.1093/annonc/mdv179

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

Review 1.  Precision Medicine and Men's Health.

Authors:  Douglas A Mata; Farhan M Katchi; Ranjith Ramasamy
Journal:  Am J Mens Health       Date:  2015-07-17

2.  Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.

Authors:  C Massard; J Mateo; Y Loriot; C Pezaro; L Albiges; N Mehra; A Varga; D Bianchini; C J Ryan; D P Petrylak; G Attard; L Shen; K Fizazi; J de Bono
Journal:  Ann Oncol       Date:  2017-01-01       Impact factor: 32.976

3.  NOREVA: enhanced normalization and evaluation of time-course and multi-class metabolomic data.

Authors:  Qingxia Yang; Yunxia Wang; Ying Zhang; Fengcheng Li; Weiqi Xia; Ying Zhou; Yunqing Qiu; Honglin Li; Feng Zhu
Journal:  Nucleic Acids Res       Date:  2020-07-02       Impact factor: 16.971

4.  Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.

Authors:  Elena Verzoni; Ugo De Giorgi; Lisa Derosa; Orazio Caffo; Francesco Boccardo; Gaetano Facchini; Luca Porcu; Fabio De Vincenzo; Alberto Zaniboni; Vincenzo Emanuele Chiuri; Lucia Fratino; Daniele Santini; Vincenzo Adamo; Rocco De Vivo; Angelo Dinota; Caterina Messina; Riccardo Ricotta; Claudia Caserta; Claudio Scavelli; Marina Susi; Alfredo Tartarone; Giuseppe Surace; Alessandra Mosca; Michele Bruno; Sandro Barni; Paolo Grassi; Giuseppe Procopio
Journal:  Oncotarget       Date:  2016-06-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.